Status:
UNKNOWN
Safety and Effectiveness of the Alma System in Treating Primary Postpartum Hemorrhage
Lead Sponsor:
ResQ Medical Ltd
Conditions:
Postpartum Hemorrhage \(PPH\)
Postpartum Hemorrhage \(Primary\)
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Postpartum Hemorrhage (PPH) is an obstetric emergency that can occur up to 24 hours after vaginal birth or cesarean section. In most cases, the uncontrolled bleeding is due to a lack of sufficient co...
Detailed Description
A prospective, non-randomized, feasibility pilot study that is intended to obtain information on the safety and effectiveness of the Alma System. Study population: Women with vaginal deliveries in a ...
Eligibility Criteria
Inclusion
- Adult Female, 18 years of age or older at time of consent.
- Subject or her legally authorized representative is able to understand and provide consent to participate in the clinical investigation.
- Subjects who present with an atonic uterus for at least 10 minutes after expulsion of placement with failure to obtain contraction and/or Subjects who have lost blood post-partum \> = 500 ml and according to the Investigator's judgment, require an intervention.
- Failed first-line intervention of uterotonics and uterine massage/bimanual uterine massage to stop bleeding.
Exclusion
- Subjects who do not provide informed consent to participate in the clinical investigation.
- Subjects who deliver at a uterus size \< 34 weeks.
- Subjects who have lost greater than 1000 ml of blood.
- Subjects who have abnormal PT, PTT and INR
- Subjects who present with retained placenta, uterine lacerations, or for any other conditions outside of atonic post-partum hemorrhage.
- PPH that the investigator determines to require more aggressive treatment, including any of the following:
- Hysterectomy;
- B-lynch suture;
- Uterine artery embolization or ligation;
- Hypogastric ligation.
- Known uterine anomaly.
- Ongoing intrauterine pregnancy.
- Placental abnormality including any of the following:
- Known placenta accreta;
- Retained placenta with known risk factors for placenta accreta (e.g., history of prior uterine surgery, including prior c-section and placenta previa);
- Retained placenta without easy manual removal.
- Known uterine rupture.
- Unresolved uterine inversion.
Key Trial Info
Start Date :
September 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06166771
Start Date
September 9 2024
End Date
June 1 2025
Last Update
October 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UNIVERSITY OF NAIROBI (UoN) COLLEGE OF HEALTH SCIENCES
Nairobi, Kenya